drugset
drugset / Trial / NCT01756404

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404 ↗

Phase 1 Completed 80 enrolled Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese volunteers.

Timeline

Start
2007-06-14
Primary completion
2007-12-05
Completion
2007-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 30 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 100 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 300 mg Oral
Subject CANAGLIFLOZIN ANHYDROUS Small molecule 600 mg Oral

Indications

No indication recorded.